In November last year, UK approved a therapy that uses the CRISPR gene editing tool to treat sickle cell disease and β-thalassaemia.
In November last year, UK approved a therapy that uses the CRISPR gene editing tool to treat sickle cell disease and β-thalassaemia.
Comments are closed.